Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate

Cell Stem Cell. 2024 Mar 7;31(3):334-340.e5. doi: 10.1016/j.stem.2024.02.001. Epub 2024 Feb 8.

Abstract

Allogeneic transplantation of pancreatic islets for patients with difficult-to-control diabetes mellitus is severely hampered by the requirement for continuous immunosuppression and its associated morbidity. We report that allogeneic transplantation of genetically engineered (B2M-/-, CIITA-/-, CD47+), primary, hypoimmune, pseudo-islets (p-islets) results in their engraftment into a fully immunocompetent, diabetic non-human primate wherein they provide stable endocrine function and enable insulin independence without inducing any detectable immune response in the absence of immunosuppression. Hypoimmune primary p-islets may provide a curative cell therapy for type 1 diabetes mellitus.

Keywords: hypoimmune; immune evasive.

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 1* / therapy
  • Humans
  • Insulin / metabolism
  • Islets of Langerhans Transplantation* / methods
  • Islets of Langerhans* / metabolism
  • Primates
  • Transplantation, Homologous

Substances

  • Insulin